 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C6H3D2I |
| Molecular Weight | 206.02 |
| Exact Mass | 205.956 |
| CAS # | 51209-48-4 |
| PubChem CID | 11575 |
| Appearance | Liquid |
| Density | 1.8±0.1 g/cm3 |
| Boiling Point | 188.3±0.0 °C at 760 mmHg |
| Melting Point | -31.3 °C |
| Flash Point | 74.4±0.0 °C |
| Vapour Pressure | 0.8±0.3 mmHg at 25°C |
| Index of Refraction | 1.620 |
| LogP | 3.25 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 0 |
| Rotatable Bond Count | 0 |
| Heavy Atom Count | 7 |
| Complexity | 46.1 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | IC1C=CC=C([2H])C=1[2H] |
| InChi Key | SNHMUERNLJLMHN-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C6H5I/c7-6-4-2-1-3-5-6/h1-5H |
| Chemical Name | iodobenzene |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1]. |
| ADME/Pharmacokinetics |
Metabolism / Metabolites The monohydroxylation of halobenzenes by phenobarbital-induced rat liver microsomes was studied. p-Halophenol was the major metabolite from all 4 halobenzenes; o-halophenol formation decreased as the halogen atom size increased. Vmax for total hydroxylation (ortho and para products) correlated well with the sigma + Hammett constant with a negative rho value. This implied a positively charged intermediate in the rate-determining step. Vmax for either ortho or para hydroxylation alone did not correlate with a Hammett constant, implying that the product-determining step occurred after the rate-determining step. Rate-determining formation of a radical cation intermediate probably explained this data. /Halobenzenes/ Detoxification of halogenobenzenes by sulfate, glucuronic-acid, and mercapturic-acid conjugation was studied. Chinchilla-rabbits received oral doses of chlorobenzene, bromobenzene, and iodobenzene equivalent to 150, 210, and 272 mg/kg, respectively ... Ethereal sulfates (E), glucuronides (G), and mercapturic-acids (M) were quantitated in rabbit urine. For chlorobenzene, the percentages of the dose excreted as conjugates were: G, 25.2; E, 26.6; and M, 20.4. For bromobenzene percentages were: G, 40.2; E, 36.8; M, 20.9. For iodobenzene, percentages were: G, 31.3; E, 29.6; M, 22.6 ... |
| Toxicity/Toxicokinetics |
Toxicity Data LC50 (rat) = 16,320 mg/m3 Interactions Hypothyroidism was produced in weanling albino rats by the oral administration of 2-thiouracil (TU) for 110 days. These animals recorded nearly 50% reduction in mitochondrial oxidation of succinate, protein content and the activity of inner mitochondrial membrane-bound beta-hydroxybutyrate dehydrogenase. Administration of iodobenzene (IB; 0.1 ug/rat/day) and L-thyroxine (T4; 0.6 ug/rat/day) to two sets of hypothyroid rats restored the reduced oxidation rate, enzyme activity and protein content to near normal values. IB was comparable to T4 and may act as a thyroid stimulant. Non-Human Toxicity Values LD50 Rat oral 1799 mg/kg |
| References |
[1]. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |
| Additional Infomation |
Mechanism of Action Iodobenzene has a bimodal effect on the receptor cell tuned to benzoic acid (BA) of the female silk moth Bombyx mori. Exposure to iodobenzene causes an inhibition of the response to BA. With stimulation by iodobenzene alone, a reduction of basic nerve impulse firing during exposure is followed by a transient post-stimulus excitation (rebound). /It was suggested/ that inhibition suppresses excitation during exposure but fades afterwards more rapidly than excitation. Due to the spatial equivalence of the iodine and the acid residue, these effects might indicate opposing interactions of iodobenzene with the specific site for the key compound BA. This is supported by the fact that substitutions by smaller halogens are less effective in both inhibition and rebound ... |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8539 mL | 24.2695 mL | 48.5390 mL | |
| 5 mM | 0.9708 mL | 4.8539 mL | 9.7078 mL | |
| 10 mM | 0.4854 mL | 2.4269 mL | 4.8539 mL |